Diagnostic utility of α-methylacyl CoA racemase (P504S) on prostate needle biopsy

Advances in Anatomic Pathology

Volumn 11, Issue 6, 2004, Pages 316-321

  Jiang, Zhong ^a   Woda, Bruce A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

methylacyl CoA racemase; AMACR; Cancer marker; P504S; Prostate carcinoma

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ALPHA-METHYLACYL-COA RACEMASE; ISOMERASE; TUMOR MARKER;

ADENOCARCINOMA; ENZYMOLOGY; HUMAN; MALE; METABOLISM; NEEDLE BIOPSY; PATHOLOGY; PROSTATE TUMOR; REVIEW;

ADENOCARCINOMA; BIOPSY, NEEDLE; HUMANS; MALE; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; TUMOR MARKERS, BIOLOGICAL;

EID: 16644401179     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/01.pap.0000146924.14246.be     Document Type: Article

References (54)

1. Wang MC, Valenzuela LA, Murphy GP, et al. A simplified purification procedure for human prostate antigen. Oncology. 1982;39:1-5. (Pubitemid 12200551)
2. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283-1290. (Pubitemid 24121936)
3. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J Urol. 1999;162:293-306. (Pubitemid 29434327)
4. Hasui Y, Marutsuka K, Asada Y, et al. Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. Prostate. 1994;25:91-96. (Pubitemid 24246110)
5. Nadler RB, Humphrey PA, Smith DS, et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995;154:407-413.
6. Epstein JI. Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol. 1995;26:223-229.
7. Algaba F, Epstein JI, Aldape HC, et al. Assessment of prostate carcinoma in core needle biopsy-definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer. 1996;78:376-381. (Pubitemid 26236279)
8. Thorson P, Humphrey PA. Minimal adenocarcinoma in prostate needle biopsy tissue. Am J Clin Pathol. 2000;114:896-909. (Pubitemid 33051890)
9. Lowe FC, Trauzzi SJ. Prostatic acid phosphatase in 1993. Its limited clinical utility. Urol Clin North Am. 1993;20:589-595. (Pubitemid 24141151)
10. Oesterling JE, Brendler CB, Epstein JI, et al. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol. 1987;138:92-98. (Pubitemid 17094451)
11. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927-935. (Pubitemid 18036141)
12. Israeli RS, Powell CT, Fair WR, et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53:227-230. (Pubitemid 23031827)
13. Teni TR, Sheth AR, Kamath MR, et al. Serum and urinary prostatic inhibin-like peptide in benign prostatic hyperplasia and carcinoma of prostate. Cancer Lett. 1988;43:9-14. (Pubitemid 19006389)
14. Edwards JJ, Anderson NG, Tollaksen SL, et al. Proteins of human urine. II. Identification by two-dimensional electrophoresis of a new candidate marker for prostatic cancer. Clin Chem. 1982;28:160-163. (Pubitemid 12209779)
15. Kim YD, Robinson DY, Manderino GL, et al. Molecular characterization of the epitope in prostate and breast tumor-associated PR92 antigen. Cancer Res. 1989;49:2379-2382. (Pubitemid 19125565)
16. Wright GL Jr, Beckett ML, Lipford GB, et al. A novel prostate carcinomaassociated glycoprotein complex (PAC) recognized by monoclonal antibody TURP-27. Int J Cancer. 1991;47:717-725.
17. Beckett ML, Lipford GB, Haley CL, et al. Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas. Cancer Res. 1991;51:1326-1333.
18. Tang DG, Honn KV. 12-Lipoxygenase, 12(S)-HETE, and cancer metastasis. Ann N Y Acad Sci. 1994;744:199-215. (Pubitemid 26005825)
19. Thomas DJ, Robinson M, King P, et al. p53 expression and clinical outcome in prostate cancer. Br J Urol. 1993;72:778-781. (Pubitemid 24000141)
20. Macri E, Loda M. Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev. 1998;17:337-344. (Pubitemid 29331783)
21. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001;412:822-826. (Pubitemid 32801464)
22. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419:624-629.
23. Rhodes DR, Sanda MG, Otte AP, et al. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst. 2003;95:661-668. (Pubitemid 36603722)
24. Brawer MK, Peehl DM, Stamey TA, et al. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res. 1985;45:3663-3667. (Pubitemid 15226442)
25. Gown AM, Vogel AM. Monoclonal antibodies to human intermediate filament proteins. II. Distribution of filament proteins in normal human tissues. Am J Pathol. 1984;114:309-321. (Pubitemid 14186855)
26. Henneberry JM, Kahane H, Humphrey PA, et al. The significance of intraluminal crystalloids in benign prostatic glands on needle biopsy. Am J Surg Pathol. 1997;21:725-728. (Pubitemid 27265762)
27. Wojno KJ, Epstein JI. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases. Am J Surg Pathol. 1995;19:251-260.
28. Signoretti S, Waltregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol. 2000;157:1769-1775.
29. Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol. 1989;13:389-396. (Pubitemid 19134069)
30. Xu J, Stolk JA, Zhang X, et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res. 2000;60:1677-1682. (Pubitemid 30183441)
31. Ferdinandusse S, Denis S. L IJ, Dacremont G, Waterham HR, Wanders RJ. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res. 2000;41:1890-1896.
32. Jiang Z, Woda BA, Rock KL, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol. 2001;25:1397-1404. (Pubitemid 33022055)
33. Rubin MA, Zhou M, Dhanasekaran SM, et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002;287:1662-1670. (Pubitemid 34289218)
34. Luo J, Zha S, Gage WR, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002;62:2220-2226. (Pubitemid 34411693)
35. Beach R, Gown AM, De Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol. 2002;26:1588-1596. (Pubitemid 35387221)
36. Leav I, McNeal JE, Ho SM, et al. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone. Hum Pathol. 2003;34:228-233. (Pubitemid 36356674)
37. Jiang Z, Wu CL, Woda BA, et al. P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol. 2002;26:1169-1174. (Pubitemid 34969186)
38. Magi-Galluzzi C, Luo J, Isaacs WB, et al. Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am J Surg Pathol. 2003;27:1128-1133. (Pubitemid 36909534)
39. Bostwick DG, Qian J, Frankel K. The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. J Urol. 1995;154:1791-1794.
40. Cheville JC, Reznicek MJ, Bostwick DG. The focus of "atypical glands, suspicious for malignancy" in prostatic needle biopsy specimens: incidence, histologic features, and clinical follow-up of cases diagnosed in a community practice. Am J Clin Pathol. 1997;108:633-640. (Pubitemid 27506229)
41. Hoedemaeker RF, Kranse R, Rietbergen JB, et al. Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions. Cancer. 1999;85:145-152. (Pubitemid 29031368)
42. Orozco R, O'Dowd G, Kunnel B, et al. Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. Urology. 1998;51:186-195. (Pubitemid 28093166)
43. Renshaw AA, Santis WF, Richie JP. Clinicopathological characteristics of prostatic adenocarcinoma in men with atypical prostate needle biopsies. J Urol. 1998;159:2018-2021.
44. Iczkowski KA, Bassler TJ, Schwob VS, Bassler IC, Kunnel BS, Orozco RE, et al. Diagnosis of "suspicious for malignancy" in prostate biopsies: predictive value for cancer. Urology. 1998;51:749-757.
45. Iczkowski KA, MacLennan GT, Bostwick DG. Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: clinical significance in 33 cases. Am J Surg Pathol. 1997;21:1489-1495. (Pubitemid 27528260)
46. Jiang Z, Iczkowski KA, Woda BA, et al. P504S immunostaining boosts diagnostic resolution of "suspicious" foci in prostatic needle biopsy specimens. Am J Clin Pathol. 2004;121:99-107. (Pubitemid 38090160)
47. Zhou M, Aydin H, Kanane H, et al. How often does alpha-methylacyl-CoA- racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am J Surg Pathol. 2004;28:239-243. (Pubitemid 38124733)
48. Sanderson SO, Sebo TJ, Murphy LM, et al. An analysis of the p63/alphamethylacyl coenzyme A racemase immunohistochemical cocktail stain in prostate needle biopsy specimens and tissue microarrays. Am J Clin Pathol. 2004;121:220-225. (Pubitemid 38140126)
49. Molinie V, Fromont G, Sibony M, et al. Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate. Mod Pathol. 2004;17:1180-1190. (Pubitemid 39312944)
50. Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer. Am J Surg Pathol. 2003;27:772-778. (Pubitemid 36617513)
51. Farinola MA, Epstein JI. Utility of immunohistochemistry for alphamethylacyl CoA racemase (AMACR) in distinguishing atrophic prostate cancer from benign atrophy. Mod Pathol. 2003;16:149A.
52. Yang XJ, Wu CL, Woda BA, et al. Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol. 2002;26:921-925. (Pubitemid 34747645)
53. Skinnider BF, Oliva E, Young RH, et al. Expression of alpha-Methylacyl-CoA Racemase (P504S) in Nephrogenic Adenoma: A Significant Immunohistochemical Pitfall Compounding the Differential Diagnosis With Prostatic Adenocarcinoma Use of p63/P504S monoclonal antibody cocktail in immunohistochemical staining of prostate tissue P63 and p504s cocktail is useful in ambiguous lesions of the prostate. Am J Surg Pathol. 2004;28:701-705.
54. Kunji LP, Rubin MA, Shen R, et al. Comparison of monoclonal antibody (P504S) and polyclonal antibody to a-methylacyl-Con A racemase in benign, atypical and malignant prostate tissues. Mod Pathol. 2003;16:158A.